Welcome to our dedicated page for Ifabric news (Ticker: IFABF), a resource for investors and traders seeking the latest updates and insights on Ifabric stock.
iFabric Corp. (OTCQX: IFABF, TSX: IFA) is active in performance apparel, advanced textiles, and fabric treatments, and its news flow reflects this focus. Through subsidiaries Intelligent Fabric Technologies (North America) Inc. (IFTNA) and Coconut Grove Pads Inc., the company announces developments in antimicrobial technologies, durable water repellents, intimate apparel, and performance-driven finished products.
News updates for iFabric often highlight technology deployments and brand partnerships. Recent releases describe license agreements and product launches involving Doctor’s Choice scrubs and medical apparel, Roots branded footwear at a Canadian wholesale club retailer, Verzus All Apparel programs, TUMI travel products featuring PROTX2, Marks & Spencer’s Autograph collections in the UK and EU, and functional bedding in collaboration with The Lad Collective.
Investors and observers can use the IFABF news stream to follow clinical validation milestones, such as the publication of a clinical trial in the Journal of Hospital Infection demonstrating statistically significant reductions in bacterial loads on PROTX2 and ecoPEL treated scrubs. Other updates cover financing and capital resources, including trade finance facilities intended to support growth and manage foreign exchange risk, as described by the company.
Coverage also includes new product category expansions for IFTNA’s technology platforms, such as moves into footwear and bedding, as well as the rollout of performance apparel brands through major retailers. For a concise view of how iFabric’s textile technologies are being adopted across apparel, healthcare, travel, and home categories, the IFABF news page aggregates these announcements in one place.
OTC Markets Group Inc. has announced that iFabric Corp. has qualified to trade on the OTCQX Best Market, upgrading from the Pink market. This move enables U.S. investors to trade under the symbol 'IFABF' as of today. The upgrade aligns with iFabric's strategy to increase transparency and accessibility for U.S. investors, especially considering its significant sales from the U.S. market. iFabric is recognized for its anti-bacterial and anti-viral textile innovations aimed at combating healthcare-acquired infections, with a focus on gaining regulatory approvals from the U.S. Environmental Protection Agency.
iFabric Corp. (IFABF) reported a significant turnaround in its Q3 2021 financial results, achieving revenues of $4.16 million, representing a 29% increase year-over-year. The Intimate Apparel Division saw a remarkable 468% increase in revenue due to normalized retail operations post-COVID. Despite an 18% revenue decrease in the Intelligent Fabrics Division, gross profit improved to 48% from 30%. Net earnings before tax turned positive at $854,556, a turnaround of nearly $1.49 million.
iFabric Corp. has engaged Independent Trading Group to provide market-making services on the Toronto Stock Exchange. This collaboration aims to enhance the liquidity and market presence of iFabric's shares, with services commencing on February 12, 2021. According to the Services Agreement, ITG will receive C$6,000 per month for an initial three-month term, followed by month-to-month renewals unless terminated with 30 days' notice. iFabric operates through subsidiaries providing performance and protective apparel, as well as ladies' intimate apparel.
iFabric Corp. announced a 5-year exclusive agreement with Beverly Hills Investments to distribute ProTX2 formulations in Africa. The deal ensures minimum annual purchases of US$2 million, US$4 million, and US$12 million over the first three years. IFTNA's AVguard, a proprietary anti-viral laundry additive, was recently donated to The Village Medical Centre in Johannesburg, promoting this partnership. The agreement aims to support health during the COVID-19 pandemic by providing effective anti-microbial solutions.
iFabric Corp. has donated the initial production of its AVguard anti-viral laundry additive to The Village Medical Centre in Johannesburg, South Africa. This product, incorporating the company's PROTX2 technology, shows over 99.9% effectiveness against SARS-CoV-2, highlighting its potential as a crucial tool in combating COVID-19 transmission. The donation is considered a stepping stone towards the product's official launch, aimed at markets with lower regulatory barriers. Dr. Paul Freinkel from The Village Medical Centre noted the significant benefits AVguard brings to healthcare practitioners.